We are the region’s only cancer center dedicated solely to the treatment and research of prostate, kidney, bladder and testicular cancers. Our team of over 30 dedicated professionals have one mission: to provide each patient unsurpassed personalized cancer care accomplished through deep heartfelt compassion, extensive and comprehensible education, the most proficient cancer management, and an unparalleled focus on improving survival and quality of life.
We utilize a unique team approach: Dr. Luke and his Clinical Team, Research Coordinators, Treatment Nurses, Pharmacy, Scheduling and Financial staff work simultaneously during a patient’s visit to ensure delivery of the most accurate, personalized, efficient and expert care.
Learn MoreDr. Luke's research team has access to potentially life-prolonging treatments years before they are available to the public. With our access to a growing pipeline of new drugs on clinical trials, UCC has the most available treatment options for urologic cancers compared to all other major centers.
Learn MoreWe understand the financial burdens cancer may cause a patient and their family. We have highly trained and compassionate staff when it comes helping you choose the most appropriate insurance plans and obtaining assistance to minimize your out- of-pocket costs.
Learn MoreSeveral weeks ago I told a prostate cancer survivors group in Ohio that going to the Urology Cancer Center in Omaha was the best prostate cancer experience that I have had since my diagnosis 5 years ago. From the first phone call to the Urology Cancer Center I knew that this was going to be different. The professional efficient and kind staff worked to overcome problems that I encountered in getting a specific new treatment. Dr. Nordquist’s approach gave me and my wife new hope in my fight.
Experts working together for your best outcome.
Cancer research is the only process available to discover and utilize new treatments for cancer patients. The Urology Center & GU Research Network is recognized by thought leaders, patients and pharmaceutical companies as a global leader in research.
Learn MoreThere is growing awareness of the problems and pitfalls with Pharmacy Benefit Managers (PBMs)
in the United States health care system. Contracted by insurance carriers to negotiate on their
behalf with pharmaceutical companies, these ‘middle men’ corporations have quietly become an
unavoidable part of our nation’s health care system.
Based on data from the phase III SPARTAN trial (ARN-509-003), apalutamide (ARN-509) has been granted a priority review by the FDA for the treatment of patients with nonmetastatic castration-resistant prostate cancer (CRPC), according to Janssen Biotech, the manufacturer of the next-generation oral androgen receptor inhibitor.
